Cargando…
Activated Ras Signaling Pathways and Reovirus Oncolysis: An Update on the Mechanism of Preferential Reovirus Replication in Cancer Cells
The development of wild-type, unmodified Type 3 Dearing strain reovirus as an anticancer agent has currently expanded to 32 clinical trials (both completed and ongoing) involving reovirus in the treatment of cancer. It has been more than 30 years since the potential of reovirus as an anticancer agen...
Autores principales: | Gong, Jun, Mita, Monica M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4071564/ https://www.ncbi.nlm.nih.gov/pubmed/25019061 http://dx.doi.org/10.3389/fonc.2014.00167 |
Ejemplares similares
-
Current understanding of reovirus oncolysis mechanisms
por: Phillips, Matthew B, et al.
Publicado: (2018) -
Potential for Improving Potency and Specificity of Reovirus Oncolysis with Next-Generation Reovirus Variants
por: Mohamed, Adil, et al.
Publicado: (2015) -
Attenuated reovirus displays oncolysis with reduced host toxicity
por: Kim, M, et al.
Publicado: (2011) -
Proteolytic Disassembly Is a Critical Determinant for Reovirus Oncolysis
por: Alain, Tommy, et al.
Publicado: (2007) -
Activation of p53 by Chemotherapeutic Agents Enhances Reovirus Oncolysis
por: Pan, Da, et al.
Publicado: (2013)